34.01

1.25% -0.43

After Hours: 33.88 -0.13 -0.38%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $34.01, with a volume of 742.66K. It is down -1.25% in the last 24 hours and up +18.83% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$34.44

Open:

$34.59

24h Volume:

742.66K

Relative Volume:

0.93

Market Cap:

$3.91B

Revenue:

$22.50M

Net Income/Loss:

$-203.82M

P/E Ratio:

-19.47

EPS:

-1.7469

Net Cash Flow:

$-148.03M

1W Performance:

+0.00%

1M Performance:

+18.83%

6M Performance:

-15.92%

1Y Performance:

+111.77%

1-Day Range:

$33.26

$34.75

1-Week Range:

$33.26

$36.73

52-Week Range:

$15.72

$42.00

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	34.01	3.96B	22.50M	-203.82M	-148.03M	-1.7469
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Apr 13, 2026

Resistance Check: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantQuarterly Trade Review & Real-Time Buy Zone Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

NewAmsterdam Pharma Company (NAMS): Huge upside potential grabs attention of billionaire Stan Druckenmiller - MSN

Apr 12, 2026

Apr 11, 2026

Pullback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity Warrant2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn

Apr 11, 2026

(NAMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 11, 2026

Published on: 2026-04-11 17:21:30 - baoquankhu1.vn

Apr 11, 2026

Apr 09, 2026

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm

Apr 09, 2026

Apr 08, 2026

NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Insider Monkey

Apr 08, 2026

Gains Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsEntry Point & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Apr 08, 2026

Does NewAmsterdam Pharma (NAMS) CETP Optimism Point To A Durable Edge In Cardiovascular Treatment? - Sahm

Apr 08, 2026

Apr 07, 2026

Short Squeeze: Will NewAmsterdam Pharma Company NV stock recover after earnings2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn

Apr 07, 2026

Billionaire Stan Druckenmiller’s 5 Small and Mid-Cap Stock Picks with Huge Upside Potential - Insider Monkey

Apr 07, 2026

Apr 06, 2026

Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Apr 06, 2026

Apr 05, 2026

Discipline and Rules-Based Execution in NAMSW Response - Stock Traders Daily

Apr 05, 2026

Will NewAmsterdam Pharma Company NV benefit from seasonality2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

NAMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Apr 04, 2026

Apr 02, 2026

Two new hires get 15,000 stock options and 3,200 RSUs at NewAmsterdam - Stock Titan

Apr 02, 2026

Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 - Insider Monkey

Apr 02, 2026

Apr 01, 2026

NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 01, 2026

Pullback Watch: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

(NAMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 31, 2026

Mar 30, 2026

Revenue Check: Does NewAmsterdam Pharma Company NV have declining or rising EPSWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn

Mar 30, 2026

Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma's (NAMS) Narrative? - Sahm

Mar 30, 2026

Mar 29, 2026

Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) - Yahoo Finance

Mar 29, 2026

Mar 25, 2026

Behavioral Patterns of NAMSW and Institutional Flows - Stock Traders Daily

Mar 25, 2026

Mar 23, 2026

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times

Mar 23, 2026

NewAmsterdam Pharma Announces Three Presentations at the - globenewswire.com

Mar 23, 2026

Mar 22, 2026

JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Mar 22, 2026

Mar 21, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 21, 2026

Mar 20, 2026

Earnings Update: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peersGap Up & Long Hold Capital Preservation Plans - baoquankhu1.vn

Mar 20, 2026

Does NewAmsterdam Pharma Company NV have declining or rising EPSEarnings Beat & AI Forecasted Stock Moves - baoquankhu1.vn

Mar 20, 2026

NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 20, 2026

(NAMS) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

Why is NewAmsterdam Pharma Company NV stock going downIPO Watch & Daily Oversold Bounce Ideas - baoquankhu1.vn

Mar 19, 2026

Truist initiates NewAmsterdam Pharma stock coverage with buy rating By Investing.com - Investing.com India

Mar 19, 2026

Mar 18, 2026

Truist initiates NewAmsterdam Pharma stock coverage with buy rating - Investing.com

Mar 18, 2026

Published on: 2026-03-19 02:35:41 - baoquankhu1.vn

Mar 18, 2026

Mar 16, 2026